Clinical Trial Search

Primary: Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL. — 3; 2 Participants

Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167

Primary: Percentage of Patients With an Overall Response to Study Drug — 24.3; 12.5 percentage of participants

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Progression-free Survival — 72 Percent

Primary: Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007) — 0 objective response

Primary: Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications — 4; 1; 3 Participants

Primary: Progression-free Survival at 1 Year — 77 percentage of participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Complete Response (CR) Rate — 64.5; 63.5 percentage of participants — p=0.915

Primary: ORR — 13 Participants

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Kaplan-Meier Estimate of Progression Free Survival (PFS) — NA; NA months — p=0.2864

Primary: Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization — 10 Participants

Primary: Overall Objective Response Rate During Treatment Cycle 1 — 57.1; 100.0; 30.8 percentage of participants

Primary: Overall Response Rate (ORR) As Measured By The Investigator — 35; 56.3; 60.0 Percentage of Participants

Primary: Maximum Tolerated Dose (MTD) — 100 mg TAK-659

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Number of Participants With Objective Response — 9 participants

Primary: Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL) — NA; NA months

Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Event-free Survival After 12 Months — 78 percentage of participants

Primary: Number of Patients Who Achieved Complete Response — 32 participants

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044

Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276